M&A Deal Summary |
|
|---|---|
| Date | 2020-09-21 |
| Target | ALPCO |
| Sector | Distribution |
| Buyer(s) | Ampersand Capital Partners |
| Deal Type | Recapitalization |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Growth Capital Firm |
|---|---|
| Founded | 1988 |
| PE ASSETS | 2.0B USD |
| Size | Large |
| Type | Sector Focused |
Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 57 of 82 |
| Sector (Distribution) | 1 of 1 |
| Type (Recapitalization) | 3 of 7 |
| State (New Hampshire) | 1 of 2 |
| Country (United States) | 52 of 67 |
| Year (2020) | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-21 |
GeneWerk
Heidelberg, Germany GeneWerk is a provider of cell and gene therapy sponsors with patient testing services in compliance with guidance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). GeneWerk was founded in 2014 and is based in Heidelberg, Germany. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-05 |
Genezen
Indianapolis, Indiana, United States Genezen is a cell and gene therapy contract development and manufacturing organization (CDMO) focused on early-phase process development, vector production, and analytical testing services. Genezen was founded in 2014 and is based in Indianapolis, Indiana. |
Buy | - |
